Effects of verapamil and adenosine in an adjunct to tirofiban on resolution and prognosis of noreflow phenomenon in patients with acute myocardial infarction

Minerva Cardioangiologica

Volumn 62, Issue 5, 2014, Pages 389-397

  Faruk Akturk, I ^a   Arif Yalcin, K A ^a   Biyik, I ^b,e   Sarikamis, C ^a   Turhan Caglar, N ^c   Erturk, M ^a   Celik, O ^a   Uzun, F ^a   Murat Caglar, I ^d   Oner, E ^a  

^a Cardiovascular Surgery Training and Research Hospital   (Turkey)

^b Usak State Hospital   (Turkey)

^c Istanbul Education and Research Hospital   (Turkey)

^d BAKIRKOY DR SADI KONUK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^e U ak Devlet Hastanesi   (Turkey)

Author keywords

Adenosine; Percutaneous coronary intervention; Verapamil

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; CLOPIDOGREL; HEPARIN; PLACEBO; TIROFIBAN; VERAPAMIL; FIBRINOLYTIC AGENT; TYROSINE; VASODILATOR AGENT;

ACUTE HEART INFARCTION; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD CLOT LYSIS; CARDIOVASCULAR MORTALITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; INTRACORONARY DRUG ADMINISTRATION; LOADING DRUG DOSE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SURVIVAL; SURVIVAL TIME; TIMI FLOW GRADE; TIMI FRAME COUNT; TRANSLUMINAL CORONARY ANGIOPLASTY; AGED; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; MORTALITY; MYOCARDIAL INFARCTION; NO-REFLOW PHENOMENON; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PROCEDURES; PROSPECTIVE STUDY; SURVIVAL RATE;

ADENOSINE; AGED; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NO-REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TYROSINE; VASODILATOR AGENTS; VERAPAMIL;

EID: 84923763898     PISSN: 00264725     EISSN: 18271618     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Reffelmann T, Kloner RA. The no-reflow phenomenon Basic science and clinical correlates. Heart 2002;87 162-8
2. Huang D, Qian J, Ge L, Jin X, Jin H, Ma J et al. Restoration of coronary flow in patients with no-reflow after primary coronary intervention of acute myocardial infarction (RECOVER). Am Heart J 2012;164 394-401
3. Niccoli G, Marino M, Spaziani C, Crea F. Prevention and treatment of no-reflow. Acute Card Care 2010,12:81-91
4. Rezkella SH, Dharmashankar KC, Abdalrahman IB, Kloner RA. No-reflow phenomenon following percutaneous coronary intervention for acute myocardial infarction-incidence, outcome and effect of pharmacologic therapy. J Interv Cardiol 2010, 23 429-36
5. Tanzilli G, Greco C, Pascen V, Pelliccia F, Arnvi A, Placanica A et al. Dipyridamole versus verapamil for treatment of no-reflow during primary angioplasty. Catheter Cardiovasc Interv 2010, 76 787-93
6. Zhao YJ, Zhao JL, You SJ, Wu YJ, Jing ZC, Yang ZC et al. Different effects of tirofiban and aspirin plus clopidogrel on myocardial no-reflow in a mmi-swine model of acute myocardial infarction and reperfusion. Heart 2006, 92 1131-7
7. Petronio AS, De Carlo M, Cibatti N, Amoroso G, Limbruno U, Palagi C et al. Left ventricular remodeling after primary coronary angioplasty in patients treated with abciximab or intracoronary adenosine. Am Heart J 2005;150:1015
8. Engler R. Consequences of activation and adenosine-mediated inhibition of granulocytes during myocardial ischemia. Fed Proc 1987, 46 2407-12.
9. Plana RN, Paik GY, Moscucci M, Cohen DJ, Gibson CM, Kugelmass AD et al. Incidence and treatment of no reflow after percutaneous coronary intervention. Circulation 1994, 89,2514-8
10. Werner GS, Lang K, Kuehnert H, Figulla HR. Intracoronary verapamil for reversal of no reflow during coronary angioplasty for acute myocardial infarction. Catheter Cardiovasc Interv 2002, 57 444-51
11. Brogden RN, Benfield P. Verapamil a review of its pharmacological properties and therapeutic use in coronary artery disease. Drugs 1996, 51:792-819.
12. Taniyama Y, Ito H, Iwakura K, Masuyama T, Hon M, Takiuchi S et al. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol 1997, 30 1193-9.
13. Steg G, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012, 33 2569-19
14. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD et al. Third universal definition of myocardial infarction. Eur Heart J 2012, 33:2551-67
15. The TIMI Study Group The Thrombolysis in Myocardial Infarction (TIMI) trial. N Engl J Med 1985, 312:932-6.
16. Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ et al. TIMI frame count a quantitative method of assessing coronary artery-flow. Circulation 1996;93 879-88
17. Gibson CM, Murphy SA, Rizzo MJ, Ryan KA, Marble SJ, McCabe CH et al. Relationship between TIMI frame count and clinical outcomes after thrombolytic administration Thrombolysis in Myocardial Infarction (TIMI) Studv Group. Circulation 1999, 99 1945-50.
18. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention-A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011, 124 e574-e651
19. Kirma C, Erkol A. Pala S, Oduncu V, Dundar C, Izgi A et al. Intracoronary bolus-only compared with intravenous bolus plus infusion of tirofiban application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Catheter Cardiovasc Interv 2012, 79 59-67.
20. Fokkema ML, Vlaar PJ, Vogelzang M, Gu YL, Kam-pinga MA, de Smet BJ et al. Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction a randomized controlled trial. Circ Cardiovasc Interv 2009;2 323-9
21. Abbo KM, Dooris M, Glazier S, O'Neill WW, Byrd D, Gnnes CL et al. No-reflow after percutaneous coronary intervention Clinical and angiographic characteristics, treatment and outcome. Am J Cardiol 1995;75 778-82.
22. Resnic FS, Wainstein M, Lee MK, Behrendt D, Wainstein RV, Ohno-Machado L et al. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J 2003, 145 42-6
23. Morishima I, Sone T, Mokuno S, Taga S, Shimauchi A, Oki Y et al. Clinical significance of no-reflow phenomenon observed on angiography after successful treatment of acute myocardial infarction with percutaneous transluminal coronary angioplasty. Am Heart J 1995; 130 239-43
24. Michaels AD, Appleby M, Otten MH, Dauterman K, Ports TA, Chou TM et al. Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: results of the randomized, controlled vasodilator prevention on no-reflow (VAPOR) trial. J Invasive Cardiol 2002, 14 299-302
25. Marzilli M, Orsini F, Maraccim R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 2000;101 2154-9
26. Barcin C, Denktas AE, Lennon RJ, Hammes L, Higano ST, Holmes DR Jr et al. Comparison of combination therapy of adenosine and nitroprusside with adenosine alone in the treatment of angiographic no-reflow phenomenon. Catheter Cardiovasc Interv 2004,61:484-91
27. Yang TY, Chang ST, Chung CM and Cheng NY. Restoration of normal coronary flow with Tirofiban by intracoronary-administration for no-reflow phenomenon after stent deployment. Int Heart J 2005, 46 139-45